| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC2836 |
| Trial ID | NCT05106946 |
| Disease | B-Cell Malignancy |
| Altered gene | CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | ThisCAR-T22 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma |
| Year | 2021 |
| Country | China |
| Company sponsor | Fundamenta Therapeutics, Ltd. |
| Other ID(s) | FT402-002 |
| Cohort 1 | |||||||||||
|
|||||||||||